Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
November 08 2022 - 4:30PM
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage,
precision-oncology biopharmaceutical company, today announced
Company’s third quarter 2022 financial results will be released on
Monday, November 14, 2022. Company management will host a
conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific
Time / 5:00 p.m. Eastern Time to discuss the financial results and
other recent corporate highlights.
Participants who wish to join the conference call by telephone
can use this link to register and receive the dial-in numbers and
unique PIN to access the call. The conference call registration and
live audio webcast can be accessed via the Investors section of the
Company’s website at www.calithera.com. Please log in approximately
5-10 minutes before the event to ensure a timely connection. The
archived webcast will remain available for replay on Calithera’s
website for 30 days.
About Calithera
Calithera Biosciences is a clinical-stage, precision oncology
biopharmaceutical company developing targeted therapies to redefine
treatment for biomarker-specific patient populations. Driven by a
commitment to rigorous science and a passion for improving the
lives of people impacted by cancer, Calithera is advancing a robust
pipeline of investigational, small-molecule oncology compounds with
a biomarker-driven approach that targets genetic vulnerabilities in
cancer cells to deliver new therapies for patients suffering from
aggressive hematologic and solid tumor cancers for which there are
currently limited treatment options.
Calithera is headquartered in South San Francisco, California.
For more information about Calithera, please visit
www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. These statements include those related to the safety,
tolerability and efficacy of Calithera’s product candidates, the
overall advancement of Calithera’s product candidates in
preclinical development and clinical trials, the unmet need in the
treatment of patients with advanced disease, and Calithera’s plans
to continue development of its product candidates. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. The potential product candidates that
Calithera develops may not progress through clinical development or
receive required regulatory approvals within expected timelines or
at all. In addition, clinical trials may not confirm any safety,
potency or other product characteristics described or assumed in
this press release. Such product candidates may not be beneficial
to patients or be successfully commercialized. The failure to meet
expectations with respect to any of the foregoing matters may have
a negative effect on Calithera's stock price. Additional
information concerning these and other risk factors affecting
Calithera's business can be found in Calithera's periodic filings
with the Securities and Exchange Commission at www.sec.gov. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, Calithera disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
CONTACTS:Stephanie Wong
ir@Calithera.com650.870.1063
INVESTORS:Burns McClellanLee
Roth212.213.0006lroth@burnsmc.com
MEDIA:Sam Brown, Inc.Hannah
Hurdle805.338.4752hannahhurdle@sambrown.com
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Dec 2023 to Dec 2024